首页
400-620-6333
IL-31
| 别名 | interleukin-31 |
|---|---|
| Compound Class | Peptide |
| 变动原因 | IL-31 is an IL-6 family cytokine. |
| Species |
Human |
| Related Product | IL-31 |
Summary
| 基因/前体 |
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 是否批准为药物？ | |||||||||||
| IUPAC Name | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide | ||||||||||
| 别名 | interleukin-31 |
数据库链接
| UniProtKB | Q6EBC2 |
|---|---|
| Wikipedia | Interleukin_31 |
| Ensembl Gene | ENSG00000204671 |
生物活性
| 生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
|---|---|
| 关联靶标 | Interleukin-31 receptor |
临床资料
| 作用机制与药效学效应 |
Sulfonamides are structural analogues of 4-aminobenzoic acid (pABA) an intermediate in the de novo synthesis of folate by some prokaryotes, lower eukaryotes and plants |
|---|
参考文献
| 1. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H, Dieu-Nosjean MC, Meller S, Rieker J et al.. (2006) IL-31: a new link between T cells and pruritus in atopic skin inflammation.. J Allergy Clin Immunol, 117 (2): (411-7). [PMID:16461142] |
| 2. Lewis KE, Holdren MS, Maurer MF, Underwood S, Meengs B, Julien SH, Byrnes-Blake KA, Freeman JA, Bukowski TR, Wolf AC et al.. (2017) Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL-31 neutralizing antibody.. J Eur Acad Dermatol Venereol, 31 (1): (142-150). [PMID:27501029] |
| 3. Storan ER, O'Gorman SM, McDonald ID, Steinhoff M. (2015) Role of cytokines and chemokines in itch.. Handb Exp Pharmacol, 226 (13): (163-76). [PMID:25861779] |
| 4. Baron JM, Lüscher B. (2012) IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis.. Acta Derm Venereol, 92 (1): (5-6). [PMID:22215012] |
| 5. Kim S, Kim HJ, Yang HS, Kim E, Huh IS, Yang JM. (2011) IL-31 Serum Protein and Tissue mRNA Levels in Patients with Atopic Dermatitis.. Ann Dermatol, 23 (4): (468-73). [PMID:22148014] |
| 6. Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B. (2012) Signaling by IL-31 and functional consequences.. Eur J Cell Biol, 91 (6-7): (552-66). [PMID:21982586] |
| 7. Lee CH, Yu HS. (2011) Biomarkers for itch and disease severity in atopic dermatitis.. Curr Probl Dermatol, 41 (13): (136-48). [PMID:21576954] |
| 8. Sprecher CA, Kuijper JK, Dasovich MM, Grant FJ, Hammond AK, Novak JE, Gross JA, Dillon SR. (2004) Novel cytokine zcytor17 ligand.. Drugs, 71 (13): (1755-70). [PMID:21902297] |
| 9. Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S, Imayama S, Kato M, Hasebe I, Taira K et al.. (2016) The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.. Br J Dermatol, 174 (2): (296-304). [PMID:26409172] |
结构
| Peptide Sequence | SHTLPVRLLRPSDDVQKIVEELQSLSKMLLKDVEEEKGVLVSQNYTLPCLSPDAQPPNNIHSPAIRAYLKTIRQLDNKSVIDEIIEHLDKLIFQDAPETNISVPTDTHECKRFILTISQQFSECMDLALKSLTSGAQQATT |
|---|---|
| Post Translation Modifications | Predicted N-linked glycosylation of asparagine residues at positions 44 and 77 |
危险品化学品经营许可证（带存储）